DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for papilloma — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePapilloma maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for papilloma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 3 (FGFR3) — FGFR3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4K33 · 2.3405 Å · ligand PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER (ACP). Experimental structure, not a prediction.
What the evidence adds up to
Surgery remains the primary treatment for inverted papilloma. In a cohort of 37 cases, the recurrence rate was 8 per cent after endoscopic surgery and 21 per cent after combined endoscopic and external approaches. The extent of disease primarily determines the choice of surgical approach, with previous treatment, individual patient factors and surgical expertise as secondary determinants.
For recurrent respiratory papillomatosis, the current standard of care is surgical therapy aimed at complete removal or debulking of papillomas while preserving normal structures. Frequent recurrences and the need for repeated surgical interventions make this a frustrating experience. Many adjuvant therapies have been investigated, but no single treatment modality has proved effective in eradicating the disease. Pharmaceutical research on human papilloma virus vaccines has been less successful than research on HIV, cytomegalovirus and hepatitis B.
A 2023 study of 73 patients with confirmed papillomatosis examined baseline variables including age of onset, breastfeeding in infancy, number of surgeries throughout life, diet, number of antibiotic treatments in the last year, BMI, and current disease activity on the three-point Dikkers scale. The analysis focused on the impact of intestinal dysbiosis on the course of papilloma.
The molecular basis of HPV-related disease involves high expression of the viral oncoproteins E6 and E7, which inhibit apoptosis, accumulate DNA damage, and activate the cell cycle. More than 99.7 per cent of cervical cancer cases in women are linked to high-risk HPV, and in men high-risk HPV predominantly contributes to a subset of oropharyngeal cancers. What is still missing is a reliably effective adjuvant therapy or vaccine for recurrent respiratory papillomatosis, along with trial designs that account for the heterogeneity of disease extent and patient factors, and adequate funding for pharmaceutical research in this rare condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Laryngology & Otology · 2000 · 89 citations · open access
Optimum management of inverted papilloma
AbstractSurgery offers the optimum modality of treatment for inverted papilloma although a considerable range of operative approaches have been described. The results are presented in a cohort of 37 cases treated by both endoscopic and combined endoscopic and external approaches with a recurrence rate of eight and 21 per cent respectively. This series is compared with those in the literature and demonstrates that it is extent of disease which primarily determines the choice of surgical approach, with previous treatment, individual patient factors and surgical expertise as secondary determinants.
Expert Opinion on Investigational Drugs · 2002 · 10 citations
Novel treatments for recurrent respiratory papillomatosis
AbstractRecurrent respiratory papillomatosis is a rare but often severe disease. Although benign in histology, epithelial proliferations may result in progressive hoarseness, stridor, obstruction of the airway and respiratory distress. The current standard of care is surgical therapy with a goal of complete removal or debulking of papillomas and preservation of normal structures. Frequent recurrences and the need for repeated surgical interventions make this treatment a frustrating experience for both the patient and the physician. Many adjuvant therapies have been investigated but no single treatment modality proved to be effective in eradicating recurrent respiratory papillomatosis. In contrast to HIV, cytomegalovirus and hepatitis B pharmaceutical research has been less successful with human papilloma virus vaccines for a variety of reasons. This review focuses on the current status of recurrent respiratory papillomatosis and on future directions of prevention and therapy.
Journal of Otolaryngology and Rhinology · 2023 · 0 citations · open access
Is There Interplay between Human Gut Microbiota and Upper Airway Susceptibility to Recurrent Respiratory Papillomatosis Exacerbations?
AbstractThe study included 73 patients with confirmed papillomatosis. The main baseline variables were: Age of onset, breastfeeding in infancy, number of surgeries throughout life, diet, number of antibiotic treatments in the last year, BMI and current disease activity on the three-point Dikkers scale. Variables important for the analysis of the impact of intestinal dysbiosis on the course of papilloma were.
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · 2022 · 0 citations
HUMAN PAPILLOMA VIRUS AND ITS REPLICATION CYCLE
AbstractHuman papilloma virus an Infected cell division and basal cell start the procedure of keratinocyte differentiation that the triggers a strongly orchestrated pattern to the productive infection of the viral gene infection (1). Ds DNA genome present in to the nuclei where in the epithelial cell dividing Cervical disease divided in to the high and low reason of the subset mucosa infective(2). Mostly high risk HPV infection during lifetime but cervical disease and cancer immune system recognizes and clear the virus (3). In men high risk human papilloma virus predomenentially a subset of or pharyngeal cancer and the women more than 99.7% in cervical cancer (4) .cancer progression is due to the persistent infection with the high risk human papilloma virus.one of the most common part cancer at the molecular level, cancer progression is due to the high expression of the viral oncoproteins E6 and E7, inhibit apoptosis and also accumulation of DNA damage and activate the cell cycle (5, 6)
AbstractIntroduction: Squamous cell papilloma is a benign tumor whose pathogenesis is generally related to the human papillomavirus. Despite affecting several organs, we did not find cases reported in the nails. Case Presentation: A 67-year-old female presented with a painful lesion in the nail of the right hallux that started in 2021, with an erythematous appearance evolving to black and expansive growth. Due to the evolution and symptoms, she opted for excision, with a histopathological report of squamous cell papilloma. Complementary treatment with imiquimod was performed, with good healing and pain control. Discussion: Due to the lack of previous reports, treatment was based on therapeutic options for papillomas located in other regions. Excision was performed, followed by application of imiquimod with good response. The prognosis is favorable; however, further studies are needed to elucidate the diagnosis and management of nail squamous cell papilloma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
